<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04678466</url>
  </required_header>
  <id_info>
    <org_study_id>MGD006-EA</org_study_id>
    <nct_id>NCT04678466</nct_id>
  </id_info>
  <brief_title>Flotetuzumab Expanded Access Program</brief_title>
  <official_title>An Expanded Access Program Providing Flotetuzumab in the Treatment of Acute Myeloid Leukemia Patients in Single, Individually-approved Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <brief_summary>
    <textblock>
      The purpose of the Expanded Access program is to provide flotetuzumab to patients with acute&#xD;
      myeloid leukemia (AML) for whom potential benefit justifies potential treatment risks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MacroGenics will consider, on a case-by-case basis, requests by treating physicians to file a&#xD;
      single patient investigational new drug application for expanded access to flotetuzumab and&#xD;
      for MacroGenics to supply flotetuzumab for single patient use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>AML</condition>
  <condition>AML, Adult Recurrent</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>flotetuzumab</intervention_name>
    <description>CD123 x CD3 bispecific DARTÂ® antibody</description>
    <other_name>MGD006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Weight of at least 17 kilograms&#xD;
&#xD;
          -  CD123-positive hematologic malignancy&#xD;
&#xD;
          -  Adequate organ reserve&#xD;
&#xD;
          -  Provider and site are trained on study protocol using flotetuzumab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AML that meets inclusion criteria for study CP-MGD006-01 (NCT02152956)&#xD;
&#xD;
          -  Primary induction failure&#xD;
&#xD;
          -  Early relapse (less than 6 months after first complete remission )&#xD;
&#xD;
          -  Three prior lines of therapy, including maximum of 1 prior salvage attempts&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ashley Ward, MD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anabela Goncalves</last_name>
    <phone>1-844-633-6469</phone>
    <email>goncalvesa@macrogenics.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

